Interface Biologics’ CSO wins NSERC award
Dr. Paul Santerre, chief scientific officer of closely-held Interface Biologics, has received a Synergy Award for Innovation during a Natural Sciences and Engineering Research Council of Canada (NSERC) awards ceremony at Rideau Hall.
Interface was founded by Dr. Santerre and is based on his groundbreaking work at the University of Toronto’s Institute of Biomaterials and Biomedical Engineering. Together, they have produced transformative biomedical polymers that improve the biocompatibility of medical devices, making them safer and more effective.
Last year, Interface’s licensing partner, Angiodynamics, received FDA clearance for BioFlo PICC with Interface’s Endexo technology.
“The Synergy Awards for Innovation recognize outstanding achievements that have resulted from partnerships between university researchers and industry,” Suzanne Fortier, president of NSERC, said in a statement. The NSERC Synergy Awards include money for a research grant as well as funding to hire an NSERC industrial R&D Fellow for two years.
Interface president and CEO Tom Reeves said the company continues to develop biomedical polymer technologies that can be applied to a myriad of clinical applications and the award is recognition of the winning partnership between Prof. Santerre, the University of Toronto, Interface and its commercial licensees.
“In conjunction with Prof. Santerre and his lab, we will be using the proceeds from the grant to continue to develop innovative technologies that can increase the safety and effectiveness of medical devices,” he added.